This study was aimed to establish clinical efficacy and tolerability of gemcitabine and cisplatin combination in patients with metastatic triple negative breast cancer progressing after anthracycline and taxane based chemotherapies. Thirty-three patients who were given cisplatin and gemcitabine for triple negative and metastatic breast cancer were evaluated retrospectively. A total of cycles were administered with a median 4 cycles per patient. Median follow-up time was 14 months range, months. Objective response rate was Total clinical benefit of the combination was
Anthracyclines is a class of drugs  used in cancer chemotherapy that are extracted from Streptomyces bacterium. The first anthracycline discovered was daunorubicin trade name Daunomycin , which is produced naturally by Streptomyces peucetius , a species of actinobacteria. Clinically the most important anthracyclines are doxorubicin , daunorubicin , epirubicin and idarubicin.
Study record managers: refer to the Data Element Definitions if submitting registration or results information. Hide glossary Glossary Study record managers: refer to the Data Element Definitions if submitting registration or results information. Search for terms x. Save this study. Warning You have reached the maximum number of saved studies